Two ASX healthcare shares that could triple in the next year

These shares are tipped to rocket 300% to 400%.

As more quarterly reports roll in, brokers are quickly adjusting their outlooks on plenty of ASX shares. 

Two ASX healthcare shares that just received fresh guidance from the team at Morgans are Epiminder Ltd (ASX: EPI) and Saluda Medical Inc (ASX: SLD). 

Both of these ASX healthcare shares have fallen significantly in 2026, down between 48% and 60%. 

However, the team at Morgans is anticipating a bounce back for both. 

Here is what the broker had to say. 

A couple stares at the tv in shock, with the man holding the remote up ready to press a button.

Image source: Getty Images

Epiminder

Epiminder develops the Minder system, a technology currently under evaluation that aims to improve epilepsy treatment by continuously recording brain activity data to reveal previously unseen epileptic episodes.

In 2026, the ASX healthcare stock has fallen nearly 50%. 

However, following its recent quarterly activities report, the team at Morgans has reiterated its speculative buy recommendation. 

The broker said momentum is building, with 3QFY26 activity highlighting improving execution. Morgans also highlighted DETECT enrolment and site activation are now gaining traction following a slow start.

Since 1HFY26, EPI has expanded to 18 Tier-1 US centres and increased enrolled patients to 15 (from 3 in February), remaining on track to reach 25 this month. Cash burn was lower than expected, reflecting timing of site invoicing, while runway remains intact through CY28. We adjusted FY26-28 forecasts and lowered our DCF-based target price to A$2.23 mainly on risk-free rate adjustment.

Yesterday, Epiminder shares closed trading at 54 cents per share. 

From this price, the updated target from Morgans indicates an upside potential of more than 300%. 

Saluda Medical

Saluda Medical is an ASX healthcare commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform.

Its share price is down nearly 60% year to date. 

However, a fresh price target from Morgans indicates this could rebound significantly.  

The company also released a quarterly report last week.

Morgans said the 3QFY26 activity continued to build on strong 1H performance, with accelerating US commercial momentum underpinning another revenue upgrade. 

The broker highlighted revenue growth of 13% quarter on quarter to US$23.8m (+34% year over year), supported by strong growth in implanted patients (+55% year over year), active physicians, and utilisation. 

We view the second consecutive guidance upgrade (now US$87m, +24% YoY) as evidence of improving visibility, with salesforce scaling and physician productivity continuing to trend ahead of expectations. We update FY26 forecasts in line with guidance, with our DCF-based target price lowered to A$2.94, mainly on FX and risk-free rate adjustments. SPECULATIVE BUY maintained.

This updated price target of $2.94 indicates an upside potential of 400%. 

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »